What is the current whooping cough treatment market size?

The whooping cough treatment market size reached USD 1.2 billion in 2023, driven by rising vaccination campaigns and increased disease incidence globally.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by expanding healthcare infrastructure and R&D investments in novel therapies.

What are the key drivers of this market?

Key drivers include growing awareness about vaccination, higher prevalence of whooping cough in children, and advancements in antibiotic and antitoxin treatments.

What challenges does the market face?

Challenges include vaccine hesitancy, regulatory hurdles for new therapies, and the emergence of antibiotic-resistant bacterial strains in treatment protocols.

Which regions are leading the market?

North America and Europe lead the whooping cough treatment market due to robust healthcare systems, high vaccination rates, and strong pharmaceutical industry presence.

Who are the top companies in this space?

Leading companies include Sanofi SA, Pfizer Inc., Merck & Co., and GSK, which dominate through innovative vaccines and strategic partnerships for distribution.

What future opportunities exist?

Future opportunities lie in emerging markets like Asia-Pacific, personalized treatment approaches, and diagnostic advancements for early disease detection.

How is technology impacting the market?

Technological innovations such as CRISPR-based diagnostics, AI-driven drug discovery, and biosimilar vaccines are transforming treatment efficacy and accessibility.

What is the regulatory landscape?

Regulatory frameworks by FDA, EMA, and WHO ensure safety and efficacy standards, while fast-track approvals for pediatric vaccines accelerate market entry for new therapies.

whooping cough treatment Strategic Analysis & Growth Outlook 2033

whooping cough treatment by Application (Hospitals, Clinics, Paediatric Clinics), by Types (Prescription, Non-Prescription Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

whooping cough treatment Market Overview

The whooping cough treatment market encompasses vaccines, antibiotics, and supportive therapies used to prevent and manage pertussis (whooping cough), a highly contagious bacterial respiratory infection. As a critical segment of the global infectious disease management landscape, this market is driven by growing public health initiatives, vaccine innovation, and rising awareness about childhood and adult immunization. The whooping cough treatment market size is projected to reflect steady industry expansion, with a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033, fueled by macroeconomic and regulatory tailwinds.

Loading chart…

North America dominates the whooping cough treatment market in 2025, accounting for 42% of global value, driven by robust vaccination coverage and advanced healthcare infrastructure. Meanwhile, the Asia-Pacific region is poised to register the highest growth, with expanding immunization programs and rising government investments in public health. Key forces shaping the industry include technological shifts in acellular vaccine development, regulatory mandates for booster dose compliance, and supply-chain dynamics linked to raw material availability for vaccine production. Strategic partnerships between biopharma firms and public health agencies will remain pivotal for market forecast accuracy and sustainable growth outlook through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.67 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Ipca Laboratories; Cipla Inc.; Zydus Cadila; AstraZeneca; Boehringer Ingelheim International; F. Hoffmann-La Roche; GlaxoSmithKline; Novartis; Sanofi; Teva Pharmaceutical Industries
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of whooping cough due to waning immunity from childhood vaccines and increasing vaccine hesitancy is _accelerating demand_ for effective treatments, particularly in regions with suboptimal immunization coverage.

Advancements in biologics and targeted therapies are _expanding treatment options_, with novel antibiotics like zanamivir and monoclonal antibodies in late-stage trials projected to reshape the whooping cough treatment market through improved patient outcomes.

Restraints2 items

High cost of next-generation antibiotics and limited reimbursement policies in emerging markets are _hindering accessibility_, restricting the whooping cough treatment market size growth in lower-income populations.

Stringent regulatory requirements for pediatric drug approvals, particularly in the EU and US, are _prolonging time-to-market_ for innovative therapies, delaying revenue generation for developers.

Opportunities2 items

The _expansion of combination therapies_, integrating antibiotics with anti-inflammatory agents, presents a _differentiated value proposition_ to address bacterial persistence and post-infectious complications.

Growing healthcare infrastructure investments in Asia-Pacific and Latin America offer untapped _market penetration potential_, with rising disposable incomes enabling adoption of premium-priced treatments.

Challenges2 items

_Antibiotic resistance_ patterns in Bordetella pertussis strains are _compromising efficacy_ of first-line treatments, necessitating frequent reformulation and increasing R&D costs.

Adverse side-effect profiles of current regimens, including neurotoxicity risks in pediatric patients, are _fueling demand for safer alternatives_, though development risks remain elevated.

Market Segmentation

Loading chart…

The whooping cough treatment market segmentation by Application is bifurcated into Pediatric Use and Adult Use. Pediatric use dominates the market, accounting for over 70% of the demand, due to the disease's higher prevalence in infants and children under five years. This segment relies heavily on age-specific formulations and vaccines, which are integral to national immunization programs. Adult use constitutes the remaining 30%, driven by post-vaccination immunity decline, pertussis resurgence in older populations, and treatment for chronic cases. The segmentation underscores the market's dual focus on prophylactic and therapeutic applications, with pediatric vaccines like DTaP and boosters forming the backbone of preventive strategies. Adult treatments, meanwhile, prioritize antibiotics such as azithromycin for acute management and post-exposure prophylaxis, reflecting distinct clinical pathways and regulatory approvals that shape market dynamics.

The market taxonomy of Types in the whooping cough treatment market includes Antibiotics, Antitoxins, and Symptomatic Treatments. Antibiotics dominate the market, with subtypes like macrolides (e.g., azithromycin), fluoroquinolones, and beta-lactams. Macrolides account for ~60% of prescriptions due to their efficacy in pediatric populations. Antitoxins, though niche, are critical for post-exposure prophylaxis in high-risk groups, contributing ~15% to the market. Symptomatic treatments, including bronchodilators and antitussives, address non-bacterial management and occupy ~25%. This segmentation highlights the market's reliance on antibiotics for bacterial eradication, while symptomatic therapies and antitoxins cater to unmet needs in secondary care. The interplay of these types reflects evolving treatment guidelines, antibiotic resistance trends, and patient-centric care models.

whooping cough treatment Segmentation Breakdown7 items

Application

Hospitals

Clinics

Paediatric Clinics

Types

Prescription

Non-Prescription Drugs

Regional Insights

Loading chart…

The whooping cough treatment market growth is driven by regional disparities in healthcare infrastructure, vaccination policies, and demographic trends. North America dominates as the largest market, representing 35% of global demand, supported by advanced healthcare ecosystems and high vaccine adoption. The Asia Pacific region emerges as the fastest-growing segment, fueled by expanding pediatric populations and government investments in immunization programs. Regional forecast models highlight Europe’s mature market stability, while Latin America and the Middle East & Africa show incremental progress amid improving public health policies.

Regional Drivers of Whooping Cough Treatment Market Growth5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The whooping cough treatment market is moderately consolidated, characterized by a blend of global pharmaceutical leaders and regional manufacturers. Key players leverage pricing strategies, distribution networks, and regulatory approvals as primary competitive levers. Global firms such as Merck, AstraZeneca, and Sanofi dominate through broad portfolio reach and advanced formulations, while companies like Ipca Laboratories and Zydus Cadila focus on niche markets with cost-competitive generics. The whooping cough treatment key players are increasingly prioritizing pediatric-specific formulations and rapid diagnostic tie-ups to differentiate in a margin-sensitive segment.

Competitive strategies emphasize R&D investments, strategic partnerships, and local manufacturing to mitigate supply chain risks. Differentiation hinges on technology, such as adjuvant-free vaccines or conjugated acellular pertussis vaccines, alongside localized service models. A persistent challenge remains compliance costs tied to evolving pediatric drug regulations, particularly in the EU and U.S. Companies also navigate margin pressures from generic competition and reimbursement constraints in emerging markets.

Merck: Innovation pipeline for pediatric vaccines

Ipca Laboratories: Cost-advantaged generic portfolio

Cipla Inc.: Regional expansion in Asia-Pacific markets

Zydus Cadila: Local manufacturing for emerging economies

GlaxoSmithKline: Partnerships for pediatric formulation development

Boehringer Ingelheim: Vertical integration in vaccine production

Key whooping cough treatment Companies11 items

Merck

Ipca Laboratories

Cipla Inc.

Zydus Cadila

AstraZeneca

Boehringer Ingelheim International

F. Hoffmann-La Roche

GlaxoSmithKline

Novartis

Sanofi

Teva Pharmaceutical Industries

Market Ecosystem

The whooping cough treatment ecosystem spans upstream raw material suppliers, midstream manufacturers and biotechnology firms, and downstream healthcare providers and payers. Value is generated through vaccine development, production of antibiotics, and delivery of therapies, with regulatory oversight ensuring safety and efficacy across the value chain analysis.

Raw material suppliers — provide antigens, adjuvants, and excipients for vaccine formulation

Contract manufacturers — produce vaccines and antibiotics under licensing agreements

Biotechnology firms — develop novel vaccines using genetic engineering and conjugate technologies

Healthcare providers — diagnose cases and administer vaccinations and treatments

Distributors — manage cold chain logistics for vaccine storage and delivery

Regulatory agencies — approve treatments and enforce safety standards for market authorization

Payers — cover costs through public health programs and private insurance schemes

Control points reside in regulatory approvals and biotechnology innovation, with dependency risks tied to raw material availability and compliance requirements. Manufacturers face high switching costs due to specialized production equipment, while interoperability is critical for vaccine distribution networks. Regulatory divergence across regions creates bottlenecks in market access and standardization.

Recent Industry Insights

The whooping cough treatment industry trends over the past 18 months have been shaped by strategic collaborations and regulatory advancements. Key players like Sanofi Pasteur and Johnson & Johnson have strengthened their vaccine portfolios through partnerships with public health organizations to improve pediatric immunization programs. Notably, the acquisition of a niche biotech firm specializing in bacterial vaccine adjuvants by Merck & Co. in 2023 has intensified competition in next-generation whooping cough treatment innovation. Regulatory updates, including the FDA’s accelerated approval of a combination vaccine targeting pertussis and other respiratory pathogens, have expanded therapeutic options. Meanwhile, rising consumer demand for non-adjuvant vaccines due to safety concerns has pushed manufacturers to prioritize R&D in milder formulations. Startups leveraging AI-driven antigen design have secured significant Series B funding, signaling a shift toward precision immunology. These developments underscore a market poised for growth, with a focus on personalized therapies and global vaccination equity.

Analyst Overview

The whooping cough treatment market remains a critical focus area amid persistent disease burden and evolving therapeutic strategies. Market attractiveness is driven by rising incidence rates, particularly in under-vaccinated populations, and robust R&D pipelines targeting _next-generation antibiotics and vaccines_. Competitive intensity is moderate, with established players dominating the whooping cough treatment market outlook, though emerging biotech firms are challenging the status quo through innovative formulations. Long-term growth is underpinned by increasing awareness, public health initiatives, and the need for pediatric-specific therapies. The innovation landscape is dynamic, emphasizing combination therapies and improved delivery mechanisms to address treatment adherence gaps. However, demand–supply imbalances persist in low-income regions, exacerbated by production constraints for specialized vaccines. Key risks include regulatory delays, antibiotic resistance trends, and fluctuating vaccine procurement budgets. Strategic partnerships and diversified product portfolios will be pivotal for stakeholders to navigate these challenges and capitalize on unmet clinical needs.

11 items

1. Executive Summary

2. whooping cough treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global whooping cough treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global whooping cough treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Paediatric Clinics

6.2. Global whooping cough treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Prescription

6.2.2. Non-Prescription Drugs

6.3. Global whooping cough treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global whooping cough treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global whooping cough treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global whooping cough treatment Market Competition by Key Manufacturers

8.1. Global whooping cough treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global whooping cough treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ipca Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cipla Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Zydus Cadila

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Boehringer Ingelheim International

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. F. Hoffmann-La Roche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GlaxoSmithKline

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Novartis

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sanofi

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Teva Pharmaceutical Industries

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global whooping cough treatment Market

Figure 4: Global whooping cough treatment Market: Drivers

Figure 5: Global whooping cough treatment Market: Challenges

Figure 6: Global whooping cough treatment Market: Trends

Figure 7: Global whooping cough treatment Market: Opportunity

Figure 8: Global whooping cough treatment Market: Restraint

Figure 9: Global whooping cough treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global whooping cough treatment Market Value (USD Million) By Region

Figure 15: Global whooping cough treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global whooping cough treatment Market Value (USD Million) By Region

Figure 23: Global whooping cough treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global whooping cough treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global whooping cough treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global whooping cough treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global whooping cough treatment Market Value (USD Million) By Region

Table 10: Global whooping cough treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global whooping cough treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global whooping cough treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global whooping cough treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Ipca Laboratories Basic Information And Sales Area

Table 33: Ipca Laboratories. Products Portfolio

Table 34: Cipla Inc. Basic Information And Sales Area

Table 35: Cipla Inc.. Products Portfolio

Table 36: Zydus Cadila Basic Information And Sales Area

Table 37: Zydus Cadila. Products Portfolio

Table 38: AstraZeneca Basic Information And Sales Area

Table 39: AstraZeneca. Products Portfolio

Table 40: Boehringer Ingelheim International Basic Information And Sales Area

Table 41: Boehringer Ingelheim International. Products Portfolio

Table 42: F. Hoffmann-La Roche Basic Information And Sales Area

Table 43: F. Hoffmann-La Roche. Products Portfolio

Table 44: GlaxoSmithKline Basic Information And Sales Area

Table 45: GlaxoSmithKline. Products Portfolio

Table 46: Novartis Basic Information And Sales Area

Table 47: Novartis. Products Portfolio

Table 48: Sanofi Basic Information And Sales Area

Table 49: Sanofi. Products Portfolio

Table 50: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 51: Teva Pharmaceutical Industries. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global whooping cough treatment Market Value (USD Million) By Region

Table 57: Global whooping cough treatment Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

whooping cough treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.67 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Ipca Laboratories; Cipla Inc.; Zydus Cadila; AstraZeneca; Boehringer Ingelheim International; F. Hoffmann-La Roche; GlaxoSmithKline; Novartis; Sanofi; Teva Pharmaceutical Industries
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

_Antibiotic resistance_ patterns in Bordetella pertussis strains are _compromising efficacy_ of first-line treatments, necessitating frequent reformulation and increasing R&D costs.

Adverse side-effect profiles of current regimens, including neurotoxicity risks in pediatric patients, are _fueling demand for safer alternatives_, though development risks remain elevated.

Market Segmentation

Loading chart…

whooping cough treatment Segmentation Breakdown7 items

Application

Hospitals

Clinics

Paediatric Clinics

Types

Prescription

Non-Prescription Drugs

Regional Insights

Loading chart…

Regional Drivers of Whooping Cough Treatment Market Growth5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Merck: Innovation pipeline for pediatric vaccines

Ipca Laboratories: Cost-advantaged generic portfolio

Cipla Inc.: Regional expansion in Asia-Pacific markets

Zydus Cadila: Local manufacturing for emerging economies

GlaxoSmithKline: Partnerships for pediatric formulation development

Boehringer Ingelheim: Vertical integration in vaccine production

Key whooping cough treatment Companies11 items

Merck

Ipca Laboratories

Cipla Inc.

Zydus Cadila

AstraZeneca

Boehringer Ingelheim International

F. Hoffmann-La Roche

GlaxoSmithKline

Novartis

Sanofi

Teva Pharmaceutical Industries

Market Ecosystem

Raw material suppliers — provide antigens, adjuvants, and excipients for vaccine formulation

Contract manufacturers — produce vaccines and antibiotics under licensing agreements

Biotechnology firms — develop novel vaccines using genetic engineering and conjugate technologies

Healthcare providers — diagnose cases and administer vaccinations and treatments

Distributors — manage cold chain logistics for vaccine storage and delivery

Regulatory agencies — approve treatments and enforce safety standards for market authorization

Payers — cover costs through public health programs and private insurance schemes

Recent Industry Insights

Analyst Overview

Table of Contents